Advertisement

Annals of Hematology

, Volume 89, Supplement 1, pp 51–54 | Cite as

Health-related quality of life outcomes for patients with immune thrombocytopenic purpura

  • Robert J. Klaassen
  • Nancy L. Young
Management Endpoints

Abstract

Immune thrombocytopenic purpura (ITP) is a rare disease with infrequent serious bleeding making clinical trials difficult. One solution to this problem is to use alternative outcome measures such as health-related quality of life (HRQL). This review describes the various HRQL tools available to researchers including measures that are generic (applicable to many different disease types) and disease-specific measures developed explicitly for ITP specifically detailing the Kids' ITP Tools and the ITP-patient administered questionnaire. This review describes how incorporating HRQL tools such as these will allow researchers to move forward and do methodologically sound research.

Keywords

Purpura Thrombocytopenic Idiopathic Quality of life Outcome measures 

References

  1. 1.
    Abrahamson PE, Hall SA, Feudjo-Tepie M, Mitrani-Gold FS, Logie J (2010) The incidence of idiopathic thrombocytopenic purpura (ITP) among adults: a population-based study and literature review. Eur J Haematol (in press)Google Scholar
  2. 2.
    Zeller B, Helgestad J, Hellebostad M, Kolmannskog S, Nystad T, Stensvold K et al (2000) Immune thrombocytopenic purpura in childhood in Norway: a prospective, population-based registration. Paediatr Hem Onc 17:551–558CrossRefGoogle Scholar
  3. 3.
    Kuhne T, Imbach P, Bolton-Maggs PH, Berchtold W, Blanchette V, Buchanan GR et al (2001) Newly diagnosed idiopathic thrombocytopenic purpura in childhood: an observational study. Lancet 358:2122–2125CrossRefPubMedGoogle Scholar
  4. 4.
    Kuhne T, Buchanan GR, Zimmerman S, Michaels LA, Kohan R, Berchtold W et al (2003) A prospective comparative study of 2540 infants and children with newly diagnosed idiopathic thrombocytopenic purpura (ITP) from the Intercontinental Childhood ITP Study Group. J Pediatr 143:605–608CrossRefPubMedGoogle Scholar
  5. 5.
    Lilleyman JS (1994) Intracranial haemorrhage in idiopathic thrombocytopenic purpura. Paediatric Haematology Forum of the British Society for Haematology. Arch Dis Child 71:251–253CrossRefPubMedGoogle Scholar
  6. 6.
    Neunert CE, Buchanan GR, Imbach P, Bolton-Maggs PH, Bennett CM, Neufeld EJ et al (2008) Severe hemorrhage in children with newly diagnosed immune thrombocytopenic purpura. Blood 112:4003–4008CrossRefPubMedGoogle Scholar
  7. 7.
    Portielje JE, Westendorp RG, Kluin-Nelemans HC, Brand A (2001) Morbidity and mortality in adults with idiopathic thrombocytopenic purpura. Blood 97:2549–2554CrossRefPubMedGoogle Scholar
  8. 8.
    Bolton-Maggs PH, Moon I (1997) Assessment of UK practice for management of acute childhood idiopathic thrombocytopenic purpura against published guidelines [see comments]. Lancet 350:620–623CrossRefPubMedGoogle Scholar
  9. 9.
    Cohen YC, Djulbegovic B, Shamai-Lubovitz O, Mozes B (2000) The bleeding risk and natural history of idiopathic thrombocytopenic purpura in patients with persistent low platelet counts. Arch Intern Med 160:1630–1638CrossRefPubMedGoogle Scholar
  10. 10.
    Blanchette V, Imbach P, Andrew M, Adams M, McMillan J, Wang E et al (1994) Randomised trial of intravenous immunoglobulin G, intravenous anti-D, and oral prednisone in childhood acute immune thrombocytopenic purpura [see comments]. Lancet 344:703–707CrossRefPubMedGoogle Scholar
  11. 11.
    Blanchette VS, Luke B, Andrew M, Sommerville-Nielsen S, Barnard D, de Veber B et al (1993) A prospective, randomized trial of high-dose intravenous immune globulin G therapy, oral prednisone therapy, and no therapy in childhood acute immune thrombocytopenic purpura [see comments]. J Pediatr 123:989–995CrossRefPubMedGoogle Scholar
  12. 12.
    Boyle MH, Furlong W, Feeny D, Torrance GW, Hatcher J (1995) Reliability of the Health Utilities Index–Mark III used in the 1991 cycle 6 Canadian General Social Survey Health Questionnaire. Qual Life Res 4:249–257CrossRefPubMedGoogle Scholar
  13. 13.
    Raat H, Botterweck AM, Landgraf JM, Hoogeveen WC, Essink-Bot ML (2005) Reliability and validity of the short form of the child health questionnaire for parents (CHQ-PF28) in large random school based and general population samples. J Epidemiol Commun Health 59:75–82CrossRefGoogle Scholar
  14. 14.
    Varni JW, Burwinkle TM, Seid M, Skarr D (2003) The PedsQL 4.0 as a pediatric population health measure: feasibility, reliability, and validity. Ambul Pediatr 3:329–341CrossRefPubMedGoogle Scholar
  15. 15.
    WHO Quality of Life Group (1993) Study protocol for the World Health Organization project to develop a quality of life assessment instrument (WHOQOL). Qual Life Res 2:153–159CrossRefGoogle Scholar
  16. 16.
    WHO Quality of Life Group (1995) The World Health Organization Quality of Life assessment (WHOQOL): position paper from the World Health Organization. Soc Sci Med 41:1403–1409CrossRefGoogle Scholar
  17. 17.
    Eiser C, Jenney M (2007) Measuring quality of life. Arch Dis Child 92:348–350CrossRefPubMedGoogle Scholar
  18. 18.
    Eiser C (2004) Use of quality of life measures in clinical trials. Ambul Pediatr 4:395–399CrossRefPubMedGoogle Scholar
  19. 19.
    Klaassen RJ, Blanchette VS, Barnard D, Wakefield CD, Curtis C, Bradley CS et al (2007) Validity, reliability, and responsiveness of a new measure of health-related quality of life in children with immune thrombocytopenic purpura: the Kids' ITP Tools. J Pediatr 150:510–515CrossRefPubMedGoogle Scholar
  20. 20.
    Zhou Z, Yang L, Chen Z, Chen X, Guo Y, Wang X et al (2007) Health-related quality of life measured by the Short Form 36 in immune thrombocytopenic purpura: a cross-sectional survey in China. Eur J Haematol 78:518–523CrossRefPubMedGoogle Scholar
  21. 21.
    Snyder CF, Mathias SD, Cella D, Isitt JJ, Wu AW, Young J (2008) Health-related quality of life of immune thrombocytopenic purpura patients: results from a web-based survey. Curr Med Res Opin 24:2767–2776CrossRefPubMedGoogle Scholar
  22. 22.
    Varni JW, Limbers CA, Burwinkle TM (2007) How young can children reliably and validly self-report their health-related quality of life?: an analysis of 8, 591 children across age subgroups with the PedsQL 4.0 Generic Core Scales. Health Qual Life Outcomes 5:1CrossRefPubMedGoogle Scholar
  23. 23.
    Mathias SD, Bussel JB, George JN, McMillan R, Okano GJ, Nichol JL (2007) A disease-specific measure of health-related quality of life for use in adults with immune thrombocytopenic purpura: its development and validation. Health Qual Life Outcomes 5:11CrossRefPubMedGoogle Scholar
  24. 24.
    von Mackensen S, Nilsson C, Jankovic M, Mirra N, D'Angelo E, Borkhardt A et al (2006) Development of a disease-specific quality of life questionnaire for children & adolescents with idiopathic thrombocytopenic purpura (ITP-QoL). Pediatr Blood Cancer 47:688–691CrossRefGoogle Scholar
  25. 25.
    George JN, Mathias SD, Go RS, Guo M, Henry DH, Lyons R et al (2009) Improved quality of life for romiplostim-treated patients with chronic immune thrombocytopenic purpura: results from two randomized, placebo-controlled trials. Br J Haematol 144:409–415CrossRefPubMedGoogle Scholar
  26. 26.
    Varni JW. The PedsQL Measurement Model for the Pediatric Quality of Life Inventory. http://www.pedsql.org

Copyright information

© Springer-Verlag 2010

Authors and Affiliations

  1. 1.Division of Hematology/Oncology, Department of PediatricsChildren’s Hospital of Eastern OntarioOttawaCanada
  2. 2.School of Rural and Northern HealthLaurentian UniversitySudburyCanada

Personalised recommendations